Inhaled micronised gentamicin powder: a new delivery system

Area of Science:

• Respiratory Medicine
• Pharmacology
• Drug Delivery Systems

Background:

• Bronchoscopy is a common procedure requiring effective antibiotic prophylaxis.
• Gentamicin is an aminoglycoside antibiotic used to treat bacterial infections.
• Inhaled antibiotic delivery offers targeted lung treatment with potentially reduced systemic side effects.

Purpose of the Study:

• To compare the efficacy of inhaled micronized gentamicin powder versus nebulized gentamicin solution in achieving therapeutic concentrations in bronchoalveolar lavage fluid.
• To assess the tolerability and potential for long-term use of inhaled micronized gentamicin powder.

Main Methods:

• A randomized controlled trial involving 40 patients undergoing routine bronchoscopy.
• Patients received either inhaled micronized gentamicin powder (180 mg) or nebulized gentamicin solution (160 mg) one hour pre-procedure.
• Gentamicin levels in bronchoalveolar lavage (BAL) fluid were measured post-procedure.

Main Results:

• Similar gentamicin concentrations were detected in BAL fluid for both the micronized powder group (9.3 mg/l) and the nebulized solution group (8.0 mg/l).
• Half of the patients receiving the micronized powder experienced cough, but this did not prevent full dose administration.
• No significant differences in drug levels were observed between the two formulations.

Conclusions:

• Inhaled micronized gentamicin powder achieves comparable lung concentrations to nebulized solution.
• The dry powder formulation presents a convenient option for long-term inhaled therapy.
• Addressing the cough side effect is crucial for optimizing the clinical utility of micronized gentamicin powder.